In anticipation of the 2016 budget proposal, the White House has tipped his hand on a big priority: fight against antibiotic resistance. A fact sheet released today describes how President Barack Obama plans to double government investment in the fight against the mounting crisis resistant infections Public health medicines disseminating approximately $ 1.2 billion in funding for several federal agencies.
This amount includes $ 650 million for the National Institutes of Health (NIH) and the Authority for Advanced Biomedical Research and development (BARDA) to study the bacterial resistance mechanisms and promote the development of new antibiotics and diagnostics. NIH funding would also support a clinical trial network that would allow developers to collect drug data more easily between multiple clinics, according to the information sheet.
The US Centers for Disease Control and Prevention would receive $ 280 million for monitoring and research, including the addition of 10 sites to its Emerging Infections Program. The fact sheet also shows two new programs :. A detection network to identify new outbreaks and a comprehensive approach "isolate bank" to collect known resistant bacteria
Meanwhile, the Food and Drug Administration will receive 47 million $ to evaluate new drugs and diagnostics and to continue its efforts to eliminate the use of certain antibiotics in animal feed, a major threat to the value of these drugs as human medicines. The Ministry of Agriculture also see a quadrupling of its funding to explore alternatives to the use of antibiotics in livestock.
The overall approach follows closely the recommendations of a recent report by the Council Chairman of Advisors on Science and Technology, says Amanda Jezek, vice president of public policy at the Infectious Diseases Society of America in Washington, DC "this appears to be what we expected in terms of next steps," she said.
proposal is the latest international effort to revitalize research and development drug-industry historically inhospitable antibiotics for major pharmaceutical companies. the short-term treatment with antibiotics and doctors' desire to retain the most effective drugs for future emergencies make it difficult for companies to make profits. and in scientific research to identify new targets for antibacterial drugs, "the low-hanging fruit has been picked," says Gail Cassell, an executive pharmaceutical company and a visiting scholar at Harvard Medical School who chairs a working group on antimicrobial resistance to the American Society for Microbiology.
But the new funding is likely to stimulate development, said Cassell, who praises in particular the emphasis placed by the White House on new diagnostics. Doctors are desperate means for detecting resistant microbes and choose the right treatment quickly, without waiting days for lab results. Earlier this year, the White House announced that the NIH and BARDA would co-sponsor a price of $ 20 million for a quicker test to recognize highly resistant infections. But Cassell stresses that developing societies, these technologies face other obstacles including the health-care reimbursement complexities for their products that can not be treated with a financial boost from the government alone.
jãzëk expects that part of the budget proposal met with sympathetic ears in Congress, both the House of Representatives and the Senate have the priority to the issue and proposed legislation to create a route 'accelerated approval for new antibiotics, she said. "The image of the federal budget will be difficult," she said, but the jockey for new funds, the proposal "represents a better chance than most."
The initiative of antibiotics will be part of the request of Obama budget to be fully unveiled on February 2, 2016 for the fiscal year that begins in October.
Click here to see all of our coverage of the 2016 budget
0 Komentar